Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110370 · ClinicalTrials.gov registry record · Phase 4
Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT00110370 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants.
The verdict
NCT00110370, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Lispro Mixture Therapy (insulin lispro 50/50 given three times daily with meals) to Glargine Basal-Bolus Therapy (insulin glargine daily with the addition of insulin lispro given three times daily with meals). The study is also comparing two different methods for adjusting the dose of insulin.
Interventions
- DRUG Lispro Mixture Therapy
- DRUG Glargine Basal-Bolus Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110370
The ClinicalTrials.gov registry entry for NCT00110370 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lispro Mixture Therapy is the first listed.
NCT00110370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110370 about?
NCT00110370 is a clinical study titled "Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes". The purpose of this study is to compare Lispro Mixture Therapy (insulin lispro 50/50 given three times daily with meals) to Glargine Basal-Bolus Therapy (insulin glargine daily with the addition of insulin lispro given three times daily with meals). The study is also comparing two different methods ...
What is the current status of trial NCT00110370?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2004-04. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00110370?
The interventions under investigation include: Lispro Mixture Therapy (DRUG), Glargine Basal-Bolus Therapy (DRUG).
Who is sponsoring clinical trial NCT00110370?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.